Insider · CIK 0001744573

Allouche Cyril

Reports to the SEC for 1 company · NEWARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001744573

Forms 4 and 5

Insider transactions

18 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2019-03-18	Revance Therapeutics, Inc.S Sale	Principal Accounting Officer	SSale	−498 sh	$15.48	−$7,709.04	6,400
2019-03-15	Revance Therapeutics, Inc.F Tax Payment	Principal Accounting Officer	FTax Payment	−252 sh	$15.45	−$3,893.4	6,898
2019-01-24	Revance Therapeutics, Inc.A Award	Principal Accounting Officer	AAward	+3,150 sh	—	—	7,150
2019-01-24	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Principal Accounting Officer	AAward	+6,500 sh	—	—	6,500
2019-01-22	Revance Therapeutics, Inc.S Sale	Principal Accounting Officer	SSale	−625 sh	$17.77	−$11.1K	4,000
2019-01-22	Revance Therapeutics, Inc.M Exercise/Conversion	Principal Accounting Officer	MExercise/Conversion	+625 sh	$13.35	+$8,343.75	4,625
2019-01-22	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Principal Accounting Officer	MExercise/Conversion	−625 sh	—	—	6,875
2019-01-03	Revance Therapeutics, Inc.S Sale	Principal Accounting Officer	SSale	−375 sh	$19.48	−$7,305	4,000
2018-12-31	Revance Therapeutics, Inc.J Other	Principal Accounting Officer	JOther	+375 sh	$17.11	+$6,416.437	4,375
2018-11-20	Revance Therapeutics, Inc.S Sale	Principal Accounting Officer	SSale	−491 sh	$20.66	−$10.1K	4,000
2018-11-15	Revance Therapeutics, Inc.F Tax Payment	Principal Accounting Officer	FTax Payment	−259 sh	$20.99	−$5,436.41	4,491
2018-11-09	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Principal Accounting Officer	MExercise/Conversion	−2,188 sh	—	—	7,500
2018-11-09	Revance Therapeutics, Inc.M Exercise/Conversion	Principal Accounting Officer	MExercise/Conversion	+2,188 sh	$13.35	+$29.2K	6,938
2018-11-09	Revance Therapeutics, Inc.S Sale	Principal Accounting Officer	SSale	−2,188 sh	$23.72	−$51.9K	4,750
2018-07-06	Revance Therapeutics, Inc.S Sale	Principal Accounting Officer	SSale	−393 sh	$28.35	−$11.1K	4,750
2018-06-29	Revance Therapeutics, Inc.J Other	Principal Accounting Officer	JOther	+393 sh	$23.33	+$9,169.673	5,143
2018-06-20	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Principal Accounting Officer	AAward	+9,500 sh	—	—	9,500
2018-06-20	Revance Therapeutics, Inc.A Award	Principal Accounting Officer	AAward	+250 sh	—	—	4,750

Recent filings

Accepted (ET)
Mar 194
Allouche Cyril0001479290-19-000036
SEC(opens sec.gov)
Jan 254
Allouche Cyril0001479290-19-000015
SEC(opens sec.gov)
Jan 234
Allouche Cyril0001479290-19-000010
SEC(opens sec.gov)
Jan 44
Allouche Cyril0001479290-19-000006
SEC(opens sec.gov)
Jan 24
Allouche Cyril0001479290-19-000002
SEC(opens sec.gov)
Nov 214
Allouche Cyril0001479290-18-000121
SEC(opens sec.gov)
Nov 164
Allouche Cyril0001479290-18-000116
SEC(opens sec.gov)
Nov 94
Allouche Cyril0001479290-18-000114
SEC(opens sec.gov)
Jul 64
Allouche Cyril0001479290-18-000095
SEC(opens sec.gov)
Jul 34
Allouche Cyril0001479290-18-000093
SEC(opens sec.gov)
Jun 224
Allouche Cyril0001479290-18-000089
SEC(opens sec.gov)

Companies

Revance Therapeutics, Inc.Principal Accounting Officer

Address

C/O REVANCE THERAPEUTICS, INC 7555 GATEWAY BLVD

NEWARK, CA, 94560